Literature DB >> 16141411

Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages.

E Rigamonti1, L Helin, S Lestavel, A L Mutka, M Lepore, C Fontaine, M A Bouhlel, S Bultel, J C Fruchart, E Ikonen, V Clavey, B Staels, G Chinetti-Gbaguidi.   

Abstract

Liver X receptors (LXRs) are nuclear receptors that regulate macrophage cholesterol efflux by inducing ATP-binding cassette transporter A1 (ABCA1) and ABCG1/ABCG4 gene expression. The Niemann-Pick C (NPC) proteins NPC1 and NPC2 are located in the late endosome, where they control cholesterol trafficking to the plasma membrane. The mobilization of cholesterol from intracellular pools to the plasma membrane is a determinant governing its availability for efflux to extracellular acceptors. Here we investigated the influence of LXR activation on intracellular cholesterol trafficking in primary human macrophages. Synthetic LXR activators increase the amount of free cholesterol in the plasma membrane by inducing NPC1 and NPC2 gene expression. Moreover, ABCA1-dependent cholesterol efflux induced by LXR activators was drastically decreased in the presence of progesterone, which blocks postlysosomal cholesterol trafficking, and reduced when NPC1 and NPC2 mRNA expression was depleted using small interfering RNA. The stimulation of cholesterol mobilization to the plasma membrane by LXRs led to a decrease in cholesteryl ester formation and Acyl-coenzyme A cholesterol acyltransferase-1 activity. These data indicate that LXR activation enhances cholesterol trafficking to the plasma membrane, where it becomes available for efflux, at the expense of esterification, thus contributing to the overall effects of LXR agonists in the control of macrophage cholesterol homeostasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16141411     DOI: 10.1161/01.RES.0000184678.43488.9f

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  42 in total

Review 1.  Role of the steroidogenic acute regulatory protein in health and disease.

Authors:  Pulak R Manna; Cloyce L Stetson; Andrzej T Slominski; Kevin Pruitt
Journal:  Endocrine       Date:  2015-08-14       Impact factor: 3.633

Review 2.  Sterol regulation of metabolism, homeostasis, and development.

Authors:  Joshua Wollam; Adam Antebi
Journal:  Annu Rev Biochem       Date:  2011       Impact factor: 23.643

Review 3.  Liver X receptors as integrators of metabolic and inflammatory signaling.

Authors:  Noam Zelcer; Peter Tontonoz
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

4.  Nuclear receptor DHR96 acts as a sentinel for low cholesterol concentrations in Drosophila melanogaster.

Authors:  Mattéa Bujold; Akila Gopalakrishnan; Emma Nally; Kirst King-Jones
Journal:  Mol Cell Biol       Date:  2009-11-23       Impact factor: 4.272

Review 5.  Novel HDL-directed pharmacotherapeutic strategies.

Authors:  Emil M Degoma; Daniel J Rader
Journal:  Nat Rev Cardiol       Date:  2011-01-18       Impact factor: 32.419

Review 6.  Niemann-Pick C2 (NPC2) and intracellular cholesterol trafficking.

Authors:  Judith Storch; Zhi Xu
Journal:  Biochim Biophys Acta       Date:  2009-02-13

7.  The Drosophila DHR96 nuclear receptor binds cholesterol and regulates cholesterol homeostasis.

Authors:  Michael A Horner; Keith Pardee; Suya Liu; Kirst King-Jones; Gilles Lajoie; Aled Edwards; Henry M Krause; Carl S Thummel
Journal:  Genes Dev       Date:  2009-12-01       Impact factor: 11.361

Review 8.  Regulation of macrophage function in inflammation and atherosclerosis.

Authors:  Norihito Shibata; Christopher K Glass
Journal:  J Lipid Res       Date:  2008-11-05       Impact factor: 5.922

9.  Overexpression of STARD3 in human monocyte/macrophages induces an anti-atherogenic lipid phenotype.

Authors:  Faye Borthwick; Anne-Marie Allen; Janice M Taylor; Annette Graham
Journal:  Clin Sci (Lond)       Date:  2010-06-22       Impact factor: 6.124

10.  Liver x receptor: a novel therapeutic target.

Authors:  M B Patel; N A Oza; I S Anand; S S Deshpande; C N Patel
Journal:  Indian J Pharm Sci       Date:  2008 Mar-Apr       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.